237 related articles for article (PubMed ID: 12496745)
1. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
Klein CE; Gupta E; Reid JM; Atherton PJ; Sloan JA; Pitot HC; Ratain MJ; Kastrissios H
Clin Pharmacol Ther; 2002 Dec; 72(6):638-47. PubMed ID: 12496745
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
Clin Pharmacol Ther; 2002 Sep; 72(3):265-75. PubMed ID: 12235447
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
Thompson PA; Gupta M; Rosner GL; Yu A; Barrett J; Bomgaars L; Bernstein ML; Blaney SM; Mondick J
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1027-37. PubMed ID: 18278496
[TBL] [Abstract][Full Text] [Related]
4. [Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G].
Valenzuela Jiménez B; González Sales M; Escudero Ortiz V; Martínez Navarro E; Pérez Ruixo C; Rebollo Liceaga J; González Manzano R; Pérez Ruixo JJ
Farm Hosp; 2013; 37(2):111-27. PubMed ID: 23789755
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Schaaf LJ; Hammond LA; Tipping SJ; Goldberg RM; Goel R; Kuhn JG; Miller LL; Compton LD; Cisar LA; Elfring GL; Gruia G; McGovren JP; Pirotta N; Yin D; Sharma A; Duncan BA; Rothenberg ML
Clin Cancer Res; 2006 Jun; 12(12):3782-91. PubMed ID: 16778106
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
Ando Y; Ueoka H; Sugiyama T; Ichiki M; Shimokata K; Hasegawa Y
Ther Drug Monit; 2002 Feb; 24(1):111-6. PubMed ID: 11805731
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
J Clin Oncol; 2002 Aug; 20(15):3293-301. PubMed ID: 12149304
[TBL] [Abstract][Full Text] [Related]
9. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.
de Jong FA; Mathijssen RH; Xie R; Verweij J; Sparreboom A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4068-71. PubMed ID: 15217940
[TBL] [Abstract][Full Text] [Related]
10. Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.
Berg AK; Buckner JC; Galanis E; Jaeckle KA; Ames MM; Reid JM
J Clin Pharmacol; 2015 Nov; 55(11):1303-12. PubMed ID: 25975718
[TBL] [Abstract][Full Text] [Related]
11. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.
Gajjar A; Chintagumpala MM; Bowers DC; Jones-Wallace D; Stewart CF; Crews KR
Cancer; 2003 May; 97(9 Suppl):2374-80. PubMed ID: 12712459
[TBL] [Abstract][Full Text] [Related]
12. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.
Stewart CF; Zamboni WC; Crom WR; Houghton PJ
Cancer Chemother Pharmacol; 1997; 40(3):259-65. PubMed ID: 9219511
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
Slatter JG; Schaaf LJ; Sams JP; Feenstra KL; Johnson MG; Bombardt PA; Cathcart KS; Verburg MT; Pearson LK; Compton LD; Miller LL; Baker DS; Pesheck CV; Lord RS
Drug Metab Dispos; 2000 Apr; 28(4):423-33. PubMed ID: 10725311
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
de Jonge MJ; Verweij J; de Bruijn P; Brouwer E; Mathijssen RH; van Alphen RJ; de Boer-Dennert MM; Vernillet L; Jacques C; Sparreboom A
J Clin Oncol; 2000 Jan; 18(1):195-203. PubMed ID: 10623710
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
Herben VM; Schellens JH; Swart M; Gruia G; Vernillet L; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1897-905. PubMed ID: 10561231
[TBL] [Abstract][Full Text] [Related]
19. [Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity].
Tanaka H; Saito K; Mino K; Izumi K; Harada M; Isobe H
Gan To Kagaku Ryoho; 2009 Sep; 36(9):1505-9. PubMed ID: 19755821
[TBL] [Abstract][Full Text] [Related]
20. Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan.
Rivory LP; Robert J
Cancer Chemother Pharmacol; 1995; 36(2):176-9. PubMed ID: 7767955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
